Trial purpose
Cancer treatment
Tumor type
Genitourinary
Age
18+
Clinical summary
Summary
The aim of this study is to determine the activity and safety of LuPSMA radionuclide therapy. Patients with metastatic prostate cancer who have progressed despite hormonal therapy and chemotherapy, will be randomised to receive either LuPSMA radionuclide therapy (up to a maximum of 6 cycles of therapy) or cabazitaxel chemotherapy (up to a maximum of 10 cycles of therapy). 200 participants will be recruited from sites across Australia. The study will determine the effects on PSA response rate (primary endpoint), pain response, progression free survival, quality of life, and frequency and severity of adverse events. Correlative outcomes include associations between PET imaging and clinical outcomes, and biomarkers and clinical outcomes.
Conditions
This trial is treating people with castration resistant prostate cancer
Eligibility
Inclusion
-
Male aged 18 or older with metastatic adenocarcinoma of the prostate defined by:
- Documented histopathology of prostate adenocarcinoma OR
- Metastatic disease typical of prostate cancer (i.e. involving bone or pelvic lymph nodes or para-aortic lymph nodes)
- Castration-resistant prostate cancer (defined as disease progressing despite castration by orchiectomy or ongoing Luteinizing Hormone-Releasing Hormone (LHRH) analog
- Progressive disease with rising PSA on 3 consecutive measurements, and PSA ≥ 20 ng/mL
- Target or non-target lesions according to RECIST 1.1
- Prior treatment with docetaxel
- Significant PSMA avidity on 68Ga-PSMA PET/CT, defined as a minimum uptake of SUVmax 20 at a site of disease, and SUVmax > 10 at sites of measurable disease ≥10mm (unless subject to factors explaining a lower uptake, e.g. respiratory motion, reconstruction artefact)
- ECOG Performance status 0 to 2
- Assessed by a medical oncologist as suitable for chemotherapy with cabazitaxel
-
Adequate renal function:
• Cr Cl ≥ 40mL/min (Cockcroft-Gault formula)
-
Adequate bone marrow function:
- Platelets ≥ 100 x10 billion /L
- Hb ≥ 90g/L (no red blood cell transfusion in last 4 weeks)
- Neutrophils > 1.5 x10 billion/L
-
Adequate liver function:
- Bilirubin < 1.5 x upper limit of normal (ULN) (or if bilirubin is between 1.5-2x ULN, must have a normal conjugated bilirubin)
- AST or ALT ≤ 2.0 x ULN (or ≤ 5.0 x ULN in the presence of liver metastases)
- Estimated life expectancy > 12 weeks
- Study treatment both planned and able to start within 21 days of randomisation
- Willing and able to comply with all study requirements, including all treatments (cabazitaxel or Lu-PSMA); and, the timing and nature of all required assessments
- Signed, written informed consent
Exclusion
- Prostate cancer with significant sarcomatoid or spindle cell or neuroendocrine small cell components
- Site(s) of disease that are FDG positive with minimal PSMA expression defined as FDG intensity > 68Ga-PSMA activity OR 68Ga-PSMA SUVmax < 10
- Sjogren's syndrome
- Prior treatment with cabazitaxel or Lu-PSMA
- Contraindications to the use of corticosteroid treatment
- Active malignancy other than prostate cancer
- Concurrent illness, including severe infection that may jeopardise the ability of the participant to undergo the procedures outlined in this protocol with reasonable safety
- Presence of any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule, including alcohol dependence or drug abuse
- Patients who are sexually active and not willing/able to use medically acceptable forms of barrier contraception
Inclusion
- Your cancer has spread to other parts of the body (metastatic) or has grown into nearby parts of the body (locally advanced).
- You have had treatment but your cancer has gotten worse or has not responded to the treatment you have been given.
Exclusion
- You have been diagnosed with a prior or secondary type of cancer.
- You have certain types of non-cancer medical conditions.
- You have had certain treatments, surgical procedures or drugs.
Clinical trials have complex eligibility criteria, and other criteria may apply for this trial. Ask your doctor about whether this trial could be right for you.
More information
Trial Identifiers
Information on this page is partially produced from ClinicalTrials.gov *. View further details about this trial on the registry via the links below:
Trial sponsor
Prostate Cancer Foundation of Australia,Australian & New Zealand Urogenital and Prostate Cancer Trials Group Limited (ANZUP)
Scientific Title
A Randomised Phase 2 Trial of 177Lu-PSMA617 Theranostic Versus Cabazitaxel in Progressive Metastatic Castration Resistant Prostate Cancer
Get Support
You might find it helpful to speak to someone who has 'been there before'. Our Peer Connect program can provide one-on-one phone support from someone who understands what you're going through and has clinical trials experience.
Know more about Peer Connect
If you need cancer information and practical support for yourself, a carer, family or friend, contact Cancer Council to speak with an experienced health professional on 13 11 20.
Get support
Learn more about clinical trials through this collection of resources in languages other than English.
View information